These two drugs have no overlapping evidence. Ozempic is approved for type 2 diabetes and has no weight-loss indication; eloralintide's only published trial specifically excluded people with type 2 diabetes. They have never been tested in the same population, for the same purpose, at any point. That is the honest starting position, and it is more useful than a table pretending otherwise.
What each one actually is
| Eloralintide | Ozempic | |
|---|---|---|
| Status | Investigational, phase 3 | FDA approved |
| Approved for | — | Type 2 diabetes |
| Target | Amylin receptor | GLP-1 |
| Studied in | Obesity without diabetes | Type 2 diabetes |
| Weight loss | 20% at 48 wks | No weight endpoint in label |
| Diabetes data | None published | HbA1c ~−1.5 to −1.8% |
| Can you get it | No | Yes |
Read the two middle rows together. Each drug has been tested in the population the other one has not.
Why there is nothing to compare
Ozempic has no weight-loss figure to offer. It is licensed for type 2 diabetes, its label publishes no weight endpoint, and the 14.9% commonly attributed to it belongs to Wegovy — the same molecule at 2.4 mg rather than Ozempic's 2 mg ceiling.
Eloralintide has no diabetes figure to offer. Its phase 2 enrolled adults with obesity or overweight plus a weight-related comorbidity and without type 2 diabetes. Whether it lowers HbA1c, and by how much, has not been published.
So a comparison would need to put eloralintide's weight result against a weight result Ozempic does not have, or Ozempic's glycaemic result against a glycaemic result eloralintide does not have. Neither works.
The two questions people are usually asking
"Could eloralintide replace my Ozempic?" Not on current evidence. If you take Ozempic for type 2 diabetes, eloralintide has no published diabetes data at all — it has not been shown to lower blood sugar, because it has not been tested for it in a published trial. It is also not approved, so the question is theoretical.
"Is amylin an alternative to GLP-1?" This is the better question, and the answer is that it looks like an addition rather than an alternative. Amylin and GLP-1 are separate hormones with separate receptors, so the effects can stack. That is why CagriSema pairs an amylin analogue with semaglutide, and why eloralintide is being trialled alongside tirzepatide rather than against it.
The comparison that is properly matched
If your interest is weight loss, compare eloralintide with the semaglutide product that has weight as its measured endpoint: eloralintide vs Wegovy. Both were studied in people with obesity, both report weight as the primary outcome, and the figures — 20% against 14.9% — describe the same kind of thing.
If your interest is a comparison against the strongest available drug, that is eloralintide vs Zepbound, where the two nearly tie and the manufacturer is testing them together.
What Ozempic has today
- An approval and a licensed indication, with a known dose and a pharmacy that dispenses it.
- A cardiovascular indication in adults with type 2 diabetes and established cardiovascular disease.
- Insurance coverage. Diabetes drugs are paid for where weight drugs are refused, which for many people decides everything.
- Years of post-marketing data across millions of patients — the only way rare effects ever surface.
Eloralintide has a single published phase 2 in 263 people over 48 weeks. It is in phase 3 and recruiting, and cannot be prescribed.
What would change this page
A trial of eloralintide in people with type 2 diabetes would make the comparison possible, and none has been published. Given that the drug is in phase 3 with sixteen registered studies, that data may well exist before long — the pipeline is tracked in the GLP-1 pipeline tracker, and what the drug is in the eloralintide overview.
Scientific References
2 sources- 1
Billings LK, Hsia S, Bays H, et al.
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2 randomised trial (enrolment excluded type 2 diabetes)
The Lancet · 406(10520) · 2025PMID: 41207310
- 2
Novo Nordisk
Ozempic (semaglutide) — indication, dosing and self-pay pricing, NovoCare Pharmacy; verified August 2026
Manufacturer prescribing and pricing information · 2026
References open in a new tab. Content is reviewed against peer-reviewed literature as part of our editorial policy.
About the author
Editor, Modern Weight Science
Claudiu Gheorghe is the editor of Modern Weight Science. He is not a physician. His role is to synthesize peer-reviewed studies, clinical-trial data, and FDA prescribing information into clear, plain-language explanations, and to make sure every factual claim on the site traces back to a cited source. Any decision about starting, changing, or stopping a medication belongs with a licensed clinician who knows your history.
Every claim is checked against peer-reviewed research through our review process and fact-checking policy.
Frequently Asked Questions
Is eloralintide better than Ozempic?
There is no evidence that answers this, because the two have never been studied in the same population. Eloralintide's only published trial enrolled adults with obesity and specifically excluded type 2 diabetes; Ozempic is licensed only for type 2 diabetes and its label carries no weight endpoint. For a matched comparison on weight, use eloralintide against Wegovy.
Could eloralintide replace Ozempic for diabetes?
Not on published evidence. Eloralintide has no diabetes data at all — it has not been shown to lower HbA1c, because the trial that reported excluded people with type 2 diabetes. It is also investigational and cannot be prescribed. Whether an amylin drug helps glycaemic control is an open question rather than a settled no.
Is amylin an alternative to GLP-1?
It looks more like an addition. Amylin and GLP-1 are separate hormones acting on separate receptors, so their effects can add rather than compete — which is why CagriSema pairs an amylin analogue with semaglutide, and why eloralintide is being trialled alongside tirzepatide rather than against it. Two drugs on the same receptor cannot be stacked; these can.
How much weight loss does Ozempic cause compared with eloralintide?
Ozempic has no weight-loss figure in its label. It is a diabetes drug, and weight reduction appears only as a secondary observation in its trials. The 14.9% usually quoted belongs to Wegovy, the same molecule at 2.4 mg against Ozempic's 2 mg ceiling. Eloralintide reached 20% in its phase 2, but in a population Ozempic has not been compared in.
Can I take eloralintide with Ozempic?
Not currently, because eloralintide is not approved and cannot be prescribed. The mechanism would allow it — different receptors, so no competition — and combinations of amylin drugs with GLP-1 drugs are exactly what is being developed. Eloralintide's registered combination trials pair it with tirzepatide rather than semaglutide.
Continue learning
Where to read next
Not medical advice. This guide is for general education only. GLP-1 medications, dosing, and treatment suitability are decisions for you and a licensed clinician who knows your full medical history.